...
首页> 外文期刊>Allergy >Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels—A pilot study
【24h】

Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels—A pilot study

机译:鼻内给予过敏原增加特异性IgE,而Intranasal omalizumab不会增加血清IgE水平 - 飞行员研究

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background Administration of the therapeutic anti‐IgE antibody omalizumab to patients induces strong increases in IgE antibody levels. Objective To investigate the effect of intranasal administration of major birch pollen allergen Bet v 1, omalizumab or placebo on the levels of total and allergen‐specific IgE in patients with birch pollen allergy. Methods Based on the fact that intranasal allergen application induces rises of systemic allergen‐specific IgE, we performed a double‐blind placebo‐controlled pilot trial in which birch pollen allergic subjects were challenged intranasally with omalizumab, placebo or birch pollen allergen Bet v 1. Total and allergen‐specific IgE, IgG and basophil sensitivity were measured before and 8?weeks after challenge. For control purposes, total, allergen‐specific IgE levels and omalizumab‐IgE complexes as well as specific IgG levels were studied in subjects treated subcutaneously with either omalizumab or placebo. Effects of omalizumab on IgE production by IL ‐4/anti‐ CD 40‐treated PBMC s from allergic patients were studied in?vitro. Results Intranasal challenge with Bet v 1 induced increases in Bet v 1‐specific IgE levels by a median of 59.2%, and this change differed significantly from the other treatment groups ( P ?=?.016). No relevant change in allergen‐specific and total IgE levels was observed in subjects challenged with omalizumab. Addition of omalizumab did not enhance IL ‐4/anti‐ CD 40‐induced IgE production in?vitro. Significant rises in total IgE (mean IgE before: 131.83 kU /L to mean IgE after: 505.23 kU /L) and the presence of IgE‐omalizumab complexes were observed after subcutaneous administration of omalizumab. Conclusion Intranasal administration of allergen induced rises of allergen‐specific IgE levels, whereas intranasal administration of omalizumab did not enhance systemic total or allergen‐specific IgE levels.
机译:None

著录项

  • 来源
    《Allergy》 |2018年第5期|共10页
  • 作者单位

    Department of OtorhinolaryngologyMedical University of ViennaVienna Austria;

    Clinical Institute for Laboratory MedicineMedical University of ViennaVienna Austria;

    Division of ImmunopathologyMedical University of ViennaVienna Austria;

    Division of ImmunopathologyMedical University of ViennaVienna Austria;

    Division of ImmunopathologyMedical University of ViennaVienna Austria;

    Division of ImmunopathologyMedical University of ViennaVienna Austria;

    Division of ImmunopathologyMedical University of ViennaVienna Austria;

    Division of ImmunopathologyMedical University of ViennaVienna Austria;

    Division of Hematology and HemostaseologyMedical University of ViennaVienna Austria;

    Division of Hematology and HemostaseologyMedical University of ViennaVienna Austria;

    Department of OtorhinolaryngologyMedical University of ViennaVienna Austria;

    Department of OtorhinolaryngologyMedical University of ViennaVienna Austria;

    Department of OtorhinolaryngologyMedical University of ViennaVienna Austria;

    Center for Medical Statistics Informatics and Intelligent SystemsMedical University of;

    Center for Medical Statistics Informatics and Intelligent SystemsMedical University of;

    Clinical Institute for Laboratory MedicineMedical University of ViennaVienna Austria;

    Vienna Challenge ChamberVienna Austria;

    Upper Airway Research Laboratory (URL)Ghent University HospitalGhent Belgium;

    Division of ImmunopathologyMedical University of ViennaVienna Austria;

    Department of OtorhinolaryngologyMedical University of ViennaVienna Austria;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学免疫学;
  • 关键词

    allergen; half‐life; IgE; intranasal challenge; omalizumab;

    机译:过敏原;半衰期;IgE;鼻内挑战;omalizumab;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号